Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2013, with the report issued on April 17, 2013. The filing primarily announces a significant regulatory milestone regarding the development of BREOTM ELLIPTATM, a once-daily inhaled treatment for Chronic Obstructive Pulmonary Disease (COPD), developed in collaboration with Theravance, Inc.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on a regulatory advisory committee recommendation and does not contain a financial results summary.
Material Changes and Regulatory Developments
The primary material event is the recommendation by the US Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) regarding BREOTM ELLIPTATM (FF/VI 100/25 mcg):
- Efficacy Vote: The committee voted 9 for and 4 against that data provides substantial evidence to support approval for the long-term maintenance treatment of airflow obstruction in COPD patients.
- Exacerbation Reduction Vote: The committee voted 9 for and 4 against that data supports approval for the reduction of COPD exacerbations in patients with a history of exacerbations.
- Safety Vote: The committee voted 10 for and 3 against that the safety of the drug has been adequately demonstrated for the proposed indications.
The New Drug Application (NDA) was originally submitted in July 2012. The Prescription Drug User Fee Act (PDUFA) goal date for the final FDA decision is May 12, 2013.
Outlook, Management Commentary, and Risks
Management Commentary: Patrick Vallance, GSK's President of Pharmaceuticals, R&D, described the recommendation as a "crucial first step" toward making the drug available to US patients. Rick E. Winningham, CEO of Theravance, noted the collaboration is a step closer to providing an important therapeutic option after a decade of development.
Outlook: GSK and Theravance are reviewing the strategy for a future US filing for asthma, as BREO ELLIPTA is not currently proposed for asthma treatment in the US. The drug is also under review in the European Union under the trade name RELVARTM.
Risks and Contingencies:
- The FDA Advisory Committee's recommendation is non-binding; the final approval decision rests with the FDA.
- Forward-looking statements are subject to risks including delays in clinical studies, safety/efficacy issues, regulatory approval failures, and reliance on third-party manufacturers.
- Safety profile includes known class effects of ICS/LABA combinations, with common adverse events including nasopharyngitis, headache, and pneumonia.
Investor Verification Checklist
- Confirm the final FDA approval decision by the PDUFA goal date of May 12, 2013.
- Monitor the status of the European Union regulatory application for RELVARTM.
- Review the strategy and timeline for a potential US asthma filing for FF/VI.
- Assess the commercial partnership terms and revenue-sharing structure between GSK and Theravance for this asset.
- Verify the safety data regarding pneumonia and COPD exacerbations in the pivotal studies.